Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2
TMO
FY2025 Q3
Raised
Thermo Fisher Scientific Inc earnings call
Buzzberg read
Guidance raised for full-year 2025 revenue and EPS.
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
Buzzberg read Guidance raised for full-year 2025 revenue and EPS. Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps). Read full analysisCollapse analysis
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
- Full-year revenue guidance raised to $44.1-44.5B, EPS to $22.60-22.86.
- Collaboration with OpenAI to embed AI into clinical research and internal operations.
- Acquired Solventum filtration business (~$750M annual revenue) and Sanofi sterile fill-finish site.
Revenue$11.122BReported
EPS$5.79Reported
Gross margin41.83%Reported
Operating margin17.47%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
AI
OpenAI partnership to embed AI in products and internal ops.
Demand
Clinical research business returns to low single-digit growth.
Show 3 more callouts
Demand
Pharma reshoring conversations with customers are active.
Macro
Biotech funding and deal activity improving, aiding ecosystem.
Margins
Q3 EPS beat driven by strong operational performance, partly offset by acquisitions.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $11.122B | Reported |
| EPS | $5.79 | Reported |
| Gross margin | 41.83% | Reported |
| Operating margin | 17.47% | Reported |
| Free cash flow | $1.835B | Reported |
| Capex | $0.404B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Capex | FY2025 | $1.4B–$1.7B | $1.55B | Maintained |
| EPS | FY2025 | $22.60–$22.86 | $22.73 | Raised |
| Free cash flow | FY2025 | $7B | $7B | Maintained |
| Operating margin | FY2025 | 22.7%–22.8% | 22.75% | Raised |
| Revenue | FY2025 | $44.1B–$44.5B | $44.3B | Raised |
AI, capex & demand read
Management read
Upbeat
Management expressed confidence in execution, raised guidance for the full year, and highlighted strong demand from pharma and biotech customers.
Management AI read
Management discussed embedding OpenAI technology into products and services to improve clinical trial cycle times, and deploying ChatGPT Enterprise internally to drive productivity. They also mentioned co-creating capabilities leveraging data repository to add value for customers.
Investment and capacity
Management raised full-year 2025 capex guidance to $1.4-$1.7 billion net capital expenditures. They also highlighted investments in a new sterile fill-finish site in the U.S. and a manufacturing center of excellence in Mebane, North Carolina, to support reshoring and U.S. supply chain resilience.
all 8 named companies below
Companiesreturns since call
Partners
OPENAI
Partners
Mark Masper
Thermo Fisher is tightly integrating OpenAI's AI into its products and internal operations, which could accelerate drug development and enhance competitive positioning.
Evidence
“We are embedding OpenAI advanced technology into critical areas of our business, including product development, service delivery, customer engagement, and operations.”
Partners
Mark Masper
Co-location of Thermo Fisher scientists with AstraZeneca could deepen R&D collaboration and drive instrument and consumables sales.
Evidence
“The recently announced strategic partnership with AstraZeneca BioVenture Hub in Gothenburg, Sweden.”
Supply chain
Supply chain
Mark Masper
Thermo Fisher adds bioprocessing and industrial filtration capabilities, expanding its addressable market and customer base.
Evidence
“We completed our acquisition of our filtration and separation business from Solventum, which is now part of our life sciences solution segment.”
Supply chain
Mark Masper
Thermo Fisher gains a new U.S. sterile fill-finish node with built-in Sanofi volume, supporting reshoring demand.
Evidence
“We closed our acquisition of the Ridgefield, New Jersey, sterile fill finish site from Sanofi, expanding our U.S. drug product manufacturing.”
Supply chain
Mark Masper
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience. — Increases domestic capacity and may reduce reliance on Asian suppliers, pressuring competitors in the lab consumables space.
Evidence
“A high-volume, low-cost facility, this site was developed with support from the U.S. government and is capable of producing at least 40 million laboratory pipette tips per week.”
Supply chain
Mark Masper
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher. — Steers large pharma spending toward Thermo Fisher's U.S. sites and could shift market share from European CDMOs.
Evidence
“We are actively engaged in helping those customers think about new sites, how to best equip them, and support our customers in that effort.”
External signals
Supply-chain alpha · 2returns since call
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience.
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher.
Methodology & coverage
Management-only analysis. All 8 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.